Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Chemotherapy-Related Nausea and/or Vomiting, Early Stage Breast Carcinoma
Conditions
Brief summary
This pilot study seeks to understand how changes in the bacteria composition (microbiome) of the gut may be associated with the occurrence of fatigue and chemotherapy-induced nausea (CIN) in women undergoing chemotherapy for early stage breast cancer. Patients undergoing chemotherapy may experience fatigue or nausea as a result of their treatment. Known risk factors for fatigue and CIN do not explain the differences in fatigue and CIN occurrence between patients, but changes in the functions of the gut microbiome may be related to the occurrence of fatigue and CIN. This study collects stool samples from breast cancer patients before and after chemotherapy to evaluate how changes in the microbiome may be associated with fatigue and CIN.
Detailed description
PRIMARY OBJECTIVES: I. Evaluate the feasibility of patient recruitment and retention, as well as specimen collection. II. Estimate the effect size for changes in gut microbiome composition profiles and metabolites in stool as well as blood from time of first stool sample collection prior to chemotherapy (T1) to time of second stool sample collection after chemotherapy (T2) that are associated with the occurrence of fatigue and CIN. III. Evaluate associations between patient reported demographic and clinical characteristics, comorbidities at T1, and changes in gastrointestinal and neuropsychological symptoms, food intake as well as exercise from T1 to T2 with the occurrence of fatigue and CIN. OUTLINE: This is an observational study. Patients undergo collection of stool and blood samples and complete questionnaires on study.
Interventions
PROCEDUREBiospecimen Collection
Undergo collection of stool and blood samples
OTHERQuestionnaire Administration
Complete questionnaires
Sponsors
Mayo Clinic
Study design
Observational model
CASE_ONLY
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
20 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Subjects with a diagnosis of early stage breast cancer planning to receive moderate to highly emetogenic chemotherapy will be recruited at Mayo Clinic Health Systems including Mankato and Albert Lea; Mayo Clinic Arizona; Mayo Clinic Rochester (Minnesota); and Mayo Clinic Florida * At least 20 years of age * Last chemotherapy more than 3 years ago * Scheduled to receive moderate to highly emetogenic chemotherapy with or without targeted therapies including immunotherapies
Exclusion criteria
* Metastatic disease * Concurrent radiation therapy * Concurrent antibiotic treatment
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Number of patients approached | Up to 24 months | Assessed using descriptive statistics. |
| Number of patients enrolled | Up to 24 months | Assessed using descriptive statistics. |
| Number of patients who completed the questionnaires at both assessments | At baseline and 3-5 days after initiation of chemotherapy | Assessed using descriptive statistics. |
| Number of patients who provided stool samples at both assessments | At baseline and 3-5 days after initiation of chemotherapy | Assessed using descriptive statistics. |
| Bacterial composition of stool samples | Up to study completion | All stool samples will be processed for deoxyribonucleic acid extraction. The hypervariable regions V3 and V4 of the bacterial 16S ribosomal ribonucleic acid (rRNA) gene will be sequenced to determine bacterial composition. After quality control, 16S rRNA reads will be analyzed to determine operational taxonomic units (OTU) for T1 and T2 samples using QIIME software. Alpha (within sample) diversity and beta (between sample) diversity will be analyzed using nonmetric multidimensional scaling ordination and the effect size for changes in OTUs in gut microbiome composition profiles from T1 to T2 in patients who do and do not report fatigue or chemotherapy-induced nausea (CIN) at T2 as measured by questionnaire. |
| Differences in demographic between patients who do and do not report fatigue and CIN | Up to study completion | Evaluated using parametric and non-parametric tests. The changes in gastrointestinal and neuropsychological symptoms, food intake as well as exercise from T1 to T2 associated with the occurrence of fatigue and CIN will be evaluated. |
| Differences in clinical characteristics between patients who do and do not report CIN | Up to study completion | Evaluated using parametric and non-parametric tests. The changes in gastrointestinal and neuropsychological symptoms, food intake as well as exercise from T1 to T2 associated with the occurrence of CIN will be evaluated. |
| Differences in comorbidities between patients who do and do not report CIN | Up to study completion | Evaluated using parametric and non-parametric tests. The changes in gastrointestinal and neuropsychological symptoms, food intake as well as exercise from T1 to T2 associated with the occurrence of CIN will be evaluated. |
Countries
United States
Contacts
PRINCIPAL_INVESTIGATORBrenda J. Ernst, MD
Mayo Clinic
Outcome results
None listed